REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 22, 2016--
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused
on improving the lives of patients by developing best-in-class medicines
that address major unmet medical needs, announced the appointment of
Christian Waage to Heron’s Board of Directors.
“Christian’s leadership experience in the biotechnology and healthcare
industry along with his transaction experience and specialized
regulatory, legal, and financial knowledge will be invaluable to Heron,”
commented Barry D. Quart, Pharm.D., Chief Executive Officer of Heron
Therapeutics, Inc. “We are thrilled to have Christian join the Heron
team, particularly at such a transformative time for the Company.”
Mr. Waage currently serves as Managing Director at Receptos, a wholly
owned subsidiary of Celgene Corporation. Mr. Waage joined Receptos in
December 2013 as Senior Vice President and General Counsel and played an
instrumental role in its acquisition by Celgene for $7.2B in August
2015. Prior to Receptos, he served as Vice President, General Counsel
and Corporate Secretary at Websense, Inc. from July 2012 until its
acquisition by Vista Equity Partners for $1B in August 2013. In addition
to overseeing its acquisition, his responsibilities at Websense included
all legal affairs, including SEC reporting and compliance, corporate
governance, litigation and licensing operations. Prior to Websense, Mr.
Waage served as Vice President, General Counsel and Corporate Secretary
of Ardea Biosciences, Inc. from March 2008 until its acquisition by
AstraZeneca PLC for $1.3B in July 2012. Prior to Ardea Biosciences, Mr.
Waage practiced law for over a decade at DLA Piper, where he was a
partner. Mr. Waage received a J.D. from the University of San Diego
School of Law and a B.A. degree in Economics from the University of
California, San Diego.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company focused on improving
the lives of patients by developing best-in-class medicines that address
major unmet medical needs. Heron is developing novel, patient-focused
solutions that apply its innovative science and technologies to
already-approved pharmacological agents for patients suffering from
cancer or pain. Heron’s goal is to build on therapeutics with well-known
pharmacology by improving their tolerability and efficacy as well as
broadening their potential field of use. For more information, visit www.herontx.com.
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, but
are not limited to, those associated with: the projected sufficiency of
our capital position for future periods, the review of the SUSTOL NDA by
the FDA, the potential market opportunity for SUSTOL and new products
generally, expected timing and acceptance of the SUSTOL commercial
launch, the progress in the research and development of HTX-019, HTX-011
and our other programs, including the timing of preclinical, clinical,
and manufacturing activities, safety and efficacy results from our
studies, and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and Heron
takes no obligation to update or revise these statements except as may
be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160622005317/en/
Source: Heron Therapeutics, Inc.
Investor Relations and Media Contact:
Jennifer Capuzelo, 858-703-6063